TRIAL DETAIL
Phase I-II clinical trial with Imatinib Mesylate and low doses of Adriamycin in patients with gastrointestinal stromal tumours (GIST) refractory to Imatinib Mesylate.
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Phase I-II clinical trial with Imatinib Mesylate and low doses of Adriamycin in patients with gastrointestinal stromal tumours (GIST) refractory to Imatinib Mesylate. |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 01/01/2004 |
Age of Trial (yrs) 20.7 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
Chemotherapy + KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT + Traditional chemotherapy |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
GEIS-12,GEIS-GIST-01, CSTI571BES14 |
|||
Sponsor: |
Grupo GEIS (Spanish Sarcoma Research Group) |
|||
Patient Contact: |
Conde de Aranda, 20. 5ยบ drcha. 28001-Madrid E-mail: jmaurel@clinic.ub.es |
|||
Contact email: |
jmaurel@clinic.ub.es |
|||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral
Subcutaneous |
|||
Trial Notes: |
Reported as recently closed at CTOS Nov. 15, 2008. Phase I: Determine the maximum dose tolerated (MDT) and the recommended dose (RD) of adriamycin in combination with fixed doses of imatinib mesylate (STI571) in the treatment of patients with gastrointestinal stroma tumours (GIST) refractory to imatinib mesylate (STI571). Phase II: Determine the response rate and the interval passed until progression of the disease. |
|||
Trial Links |
Trial Results |
Drug Information |
| Doxorubicin in Wikipedia |
| Doxorubicin prescribing information |
| Doxorubicin in Chemocare.com |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Barcelona |
08036 |
Spain |